Module

State-of-the-Art Management of Diffuse Large B-Cell Lymphoma

Source: Promising Directions in Myeloma and Lymphoproliferative Disorders: Approaching Resistance, Retreatment, and Maintenance Through Novel Clinical Pathways

State-of-the-Art Management of Diffuse Large B-Cell Lymphoma


Program Director: Andre Goy, MD, MPH

Faculty:

  • Michael Pfreundschuh, MD

CME CREDIT INFORMATION

Release Date: 04/22/08

Expiration Date: 04/21/09


Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.0 Nursing CE credit

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain the importance of the International Prognostic Index in making treatment decisions for patients with diffuse large B-cell lymphoma
  • List the treatment options available for young patients with diffuse large B-cell lymphoma
  • Describe the impact of rituximab on the treatment of elderly patients with diffuse large B-cell lymphoma
  • Discuss alternative strategies for optimizing rituximab dosing in patients with diffuse large B-cell lymphoma
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.